Steven Cohen Bicycle Therapeutics PLC Transaction History
Point72 Asset Management, L.P.
- $51 Billion
- Q3 2025
A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Bicycle Therapeutics PLC stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 430,900 shares of BCYC stock, worth $2.79 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
430,900
Previous 1,772,600
75.69%
Holding current value
$2.79 Million
Previous $12.3 Million
72.93%
% of portfolio
0.01%
Previous 0.03%
Shares
23 transactions
Others Institutions Holding BCYC
# of Institutions
105Shares Held
38MCall Options Held
37.6KPut Options Held
3.7K-
Baker Bros. Advisors LP New York, NY10.9MShares$70.5 Million0.69% of portfolio
-
Fcpm Iii Services B.V. Naarden, P73.45MShares$22.4 Million5.34% of portfolio
-
Armistice Capital, LLC New York, NY2.98MShares$19.3 Million0.35% of portfolio
-
Westfield Capital Management CO LP Boston, MA2.95MShares$19.1 Million0.1% of portfolio
-
Siren, L.L.C. New York, NY2.01MShares$13 Million0.61% of portfolio
About BICYCLE THERAPEUTICS plc
- Ticker BCYC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,676,100
- Market Cap $192M
- Description
- Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The co...